Table 2.
Infliximab Dosing Details and Outcomes
| Infliximab dosing details and outcomes | Overall (n = 43) | 5mg/kg (n = 22) | 200mg/m2 (n = 10) | P values |
|---|---|---|---|---|
| Dose/kg | ||||
| Induction-median dose 1–3 (IQR) | 6.9 (5.4,10.4) | 5.6 (5.1, 6) | 11.9 (9.7, 17.1) | .001a |
| 1 y (IQR) | 8.2 (6.4, 10) | 7.4 (6.1, 9.8) | 8.7 (7.5, 8.7) | 1.00 |
| 2 y (IQR) | 8.7 (6.3, 9.7) | 8 (6, 9.6) | 10.9 (10.9) | .47 |
| Dose/m2 | ||||
| Induction-median dose 1–3 (IQR) | 177.4 (130.7, 283.9) | 136 (124,161.5) | 283.9 (236.8370.8) | .001a |
| 1 y (IQR) | 211.4 (170.6, 263.9) | 200 (159.8, 247.2) | 231.3 (188.5, 231.3) | 1.00 |
| 2 y (IQR) | 224.8 (164.1, 257.7) | 215.3 (161.4, 247.8) | 314.1 (314.1) | .47 |
| Infliximab level predose 4 (μg/ml) (IQR) | 12 (4.6, 28) | 5.1 (2.6, 10.7) | 18.6 (10.8, 28.1) | .04a |
| Interval dose 1 – dose 4 IFX (d), median (IQR) | 69 (56, 84) | 70 (56,87) | 58 (56, 71) | .11 |
| Infliximab cessation | 19 (44.1%) | 12 (54.5%) | 5 (50%) | 1.00 |
| Infliximab escalation | 26 (60.5%) | 18 (81.8%) | 3 (30%) | .004a |
| CSF remission | ||||
| Post induction | 13 (30.2%) | 6 (27.3%) | 3 (30%) | .87 |
| 6 mo | 20 (54.1%) | 8 (42.1%) | 4 (50%) | .71 |
| 1 y | 20 (71%) | 12 (75%) | 4 (67%) | .70 |
| 2 y | 12 (63.2%) | 10 (67%) | 2 (100%) | .33 |
| Time to stopping steroids (d), (IQR) | 67.5 (39.8, 138.5) | 106 (49.5, 178) | 53.5 (32, 99) | .65 |
| Colectomy | 6 (13.9%) | 5 (22.7%) | 1 (10%) | .39 |
CSF, corticosteroid free.
a
P < .05.